ATAD1 and malaria: Other blood-stage malaria vaccines such as MSP-1 and AMA-1 intended to block or reduce the invasion of erythrocytes by malaria merozoites (4, 49, 50) have either shown no or little protection in Phase 2b efficacy studies (51–54).